Long COVID or Post-COVID-19 Condition: Past, Present and Future Research Directions
Microorganisms · 11.12.2023 · 11 (12) · 2959
DOI: 10.3390/microorganisms11122959 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Microorganisms, online erschienen am 11.12.2023. Verfasst von César Fernández-de-Las-Peñas und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos, 28922 Madrid, Spain. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Center for Neuroplasticity and Pain (CNAP), Novo Nordisk Foundation, The University Rey Juan Carlos (URJC).
Abstract (Originalsprache)
The presence of symptoms after an acute SARS-CoV-2 infection (long-COVID) has become a worldwide healthcare emergency but remains underestimated and undertreated due to a lack of recognition of the condition and knowledge of the underlying mechanisms. In fact, the prevalence of post-COVID symptoms ranges from 50% during the first months after the infection up to 20% two-years after. This perspective review aimed to map the existing literature on post-COVID symptoms and to identify gaps in the literature to guide the global effort toward an improved understanding of long-COVID and suggest future research directions. There is a plethora of symptomatology that can be due to COVID-19; however, today, there is no clear classification and definition of this condition, termed long-COVID or post-COVID-19 condition. The heterogeneity in the symptomatology has led to the presence of groups/clusters of patients, which could exhibit different risk factors and different mechanisms. Viral persistence, long-lasting inflammation, immune dysregulation, autoimmune reactions, reactivation of latent infections, endothelial dysfunction and alteration in gut microbiota have been proposed as potential mechanisms explaining the complexity of long-COVID. In such an equation, viral biology (e.g., re-infections, SARS-CoV-2 variants), host biology (e.g., genetics, epigenetics) and external factors (e.g., vaccination) should be also considered. These various factors will be discussed in the current perspective review and future directions suggested.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Physical Therapy, Occupational Therapy, Physical Medicine and Rehabilitation, Universidad Rey Juan Carlos, 28922 Madrid, Spain.
- Center for Neuroplasticity and Pain (CNAP), Center for Sensory-Motor Interaction (SMI), Department of Health Science and Technology, Faculty of Medicine, Aalborg University, DK-9220 Aalborg, Denmark.
- Govt. Medical College, Kozhikode 676121, Kerala, India.
- Department of Medical Gastroenterology, Mech-Sense, Aalborg University Hospital, DK-9000 Aalborg, Denmark.
- Steno Diabetes Center North Denmark, Clinical Institute, Aalborg University Hospital, DK-9000 Aalborg, Denmark.
ORCID-Profile: César Fernández-de-Las-Peñas, Arkiath Veettil Raveendran, Rocco Giordano
Förderung
- Center for Neuroplasticity and Pain (CNAP)
- Novo Nordisk Foundation
- The University Rey Juan Carlos (URJC)
Zitieren
APA
Fernández-de-Las-Peñas, C., Raveendran, A. V., Giordano, R., & Arendt-Nielsen, L. (2023). Long COVID or Post-COVID-19 Condition: Past, Present and Future Research Directions. Microorganisms, 11(12), 2959. https://doi.org/10.3390/microorganisms11122959
Vancouver
Fernández-de-Las-Peñas C, Raveendran AV, Giordano R, Arendt-Nielsen L. Long COVID or Post-COVID-19 Condition: Past, Present and Future Research Directions. Microorganisms. 2023;11(12):2959. doi:10.3390/microorganisms11122959
BibTeX
@article{FernndezdeLasPeas2023,
author = {Fernández-de-Las-Peñas, César and Raveendran, Arkiath Veettil and Giordano, Rocco and Arendt-Nielsen, Lars},
title = {Long COVID or Post-COVID-19 Condition: Past, Present and Future Research Directions},
journal = {Microorganisms},
year = {2023},
volume = {11},
number = {12},
pages = {2959},
doi = {10.3390/microorganisms11122959}
}
EUVIMED